DMEM CTS™ KnockOut™
DMEM CTS™ KnockOut™
DMEM CTS™ KnockOut™
DMEM CTS™ KnockOut™
Gibco™

DMEM CTS™ KnockOut™

DMEM CTS™ KnockOut es un medio basal optimizado para el crecimiento de células madre pluripotentes inducidas y embrionarias humanas noMás información
Have Questions?
Número de catálogoCantidad
A1286101500 mL
Número de catálogo A1286101
Precio (CLP)
63.287
Each
Añadir al carro de la compra
Cantidad:
500 mL
Precio (CLP)
63.287
Each
Añadir al carro de la compra
DMEM CTS™ KnockOut es un medio basal optimizado para el crecimiento de células madre pluripotentes inducidas y embrionarias humanas no diferenciadas. La línea de productos GIBCO™ CTS™ le permite reducir la carga de cualificar los reactivos durante su transición de aplicaciones de investigación a aplicaciones clínicas.


• D-MEM definido para cultivo de células madre hESC⁄iPSC.
• Osmolaridad optimizada para el crecimiento de hESC e IPSC no diferenciadas.
• GIBCO™ KnockOut DMEM CTS™ le permite reducir la carga de cualificar los reactivos durante su transición de aplicaciones de investigación a aplicaciones clínicas.

DMEM CTS™ KnockOut es un medio basal optimizado para el crecimiento de células madre pluripotentes inducidas y embrionarias humanas no diferenciadas. La osmolaridad se ha optimizado para aproximarse a la del tejido embrionario del ratón. No contiene L-glutamina.

Los productos GIBCO™ CTS™ son de alta calidad y se suministran con documentación armonizada, como certificados de análisis, certificados de origen y acceso a cartas de autorización de nuestros archivos principales sobre fármacos, según corresponda. La línea de productos GIBCO™ CTS™ le permite reducir la carga de cualificar los reactivos durante su transición de aplicaciones de investigación a aplicaciones clínicas.
Para su uso en investigación o fabricación de productos basados en células, genes o tejidos. PRECAUCIÓN: No se ha diseñado para la administración directa en seres humanos o animales.
Especificaciones
Tipo de célulaCélulas madre (embrionarias), células madre (iPS, pluripotentes inducidas)
Para utilizar con (aplicación)Cell and Gene Therapy Research, Development, and Manufacturing
FormatoFrasco
Calidad de fabricaciónBuenas prácticas de fabricación actuales para dispositivos médicos, 21 CFR Parte 820 e ISO 13485
Tipo de productoDMEM CTS KnockOut
Cantidad500 mL
Duración de almacenamiento12 months from date of manufacture
Condiciones de envíoAmbiente
ClasificaciónCon definición química
FormularioLíquido
EsterilidadEstéril con filtro
Unit SizeEach
Contenido y almacenamiento
Almacenar entre 2 C y 8 °C y proteger de la luz.

Preguntas frecuentes

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

How do I characterize human embryonic stem ( ES) cells?

Human ES cells are generally characterized by their typical morphology (they grow as tightly packed clusters of small cells with high ratio of nucleus to cytoplasm); surface marker expression; RT-PCR detection of stem cell-specific gene expression (such as Oct3/4, Sox2, and Nanog); alkaline phosphatase staining, and telomerase activity assay. The most commonly used ES specific surface markers include stage-specific embryonic antigens SSEA-3 and SSEA-4 for human ES cells. Other ES-specific surface antigens also include TRA-1-60 and TRA-1-81. (Science 282:1145 (1998).

How are human embryonic stem (ES) cells derived?

Human ES cells are derived from human blastocyst inner cell masses, isolated by immunosurgery with rabbit antiserum to BeWO cells (a human trophoblast cell line) (Science 282:1145 (1998)).

What are ES cells?

Embryonic stem (ES) cells are derived from the early mammalian embryo and are capable of unlimited, undifferentiated proliferation in vitro while maintaining their potential to differentiate into a wide of range of adult tissues including germ cells. The pluripotency of the ES cells is normally demonstrated in vitro by inducing ES cells to differentiate into embryoid bodies and checking lineage-specific markers for differentiated cells in three body layers (endo, meso, and ectoderm), or injecting them into immunodeficient mice and determining the cell types produced in the teratomas.

How long can I keep my media after supplementing with serum?

Generally speaking, media can be used for up to three weeks after supplementation with serum. There are no formal studies to support this, but it is the rule of thumb used by our scientists.

Find additional tips, troubleshooting help, and resources within our Mammalian Cell Culture Basics Support Center.

Citations & References (1)

Citations & References
Abstract
Impact of transient down-regulation of DREAM in human embryonic stem cell pluripotency: The role of DREAM in the maintenance of hESCs.
Authors:Fontán-Lozano A, Capilla-Gonzalez V, Aguilera Y, Mellado N, Carrión AM, Soria B, Hmadcha A
Journal:Stem Cell Res
PubMed ID:26999760
'Little is known about the functions of downstream regulatory element antagonist modulator (DREAM) in embryonic stem cells (ESCs). However, DREAM interacts with cAMP response element-binding protein (CREB) in a Ca(2+)-dependent manner, preventing CREB binding protein (CBP) recruitment. Furthermore, CREB and CBP are involved in maintaining ESC self-renewal and pluripotency. However, ... More